Completed PHASE4 INTERVENTIONAL 2-arm NCT02885168

Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C (PCA)

Sponsor: Central Hospital, Nancy, France

Interventions Blood sample Near-infrared spectroscopy (NIRS) Phenylephrine Recombinant Activated Protein C

Updated 4 times since 2017 Last updated: Aug 26, 2016 Started: Feb 29, 2008 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02885168, this PHASE4 trial focuses on Septic Shock and remains completed. Sponsored by Central Hospital, Nancy, France, it has been updated 4 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central Hospital, Nancy, France

Data source: Central Hospital, Nancy, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.